Tag: Pharmaceutical competition

Alnylam Pharmaceuticals, led by CEO Yvonne Greenstreet, is making strides in expanding the use of its RNA-based gene-silencing heart drug, vutrisiran. The drug has shown promising results in reducing the risk of death and...